tomorrowread
Acurx partners with Leiden University Medical Center to map MRSA target and speed antibiotic development
Technology·Medium term

Acurx and Leiden UMC will publish MRSA PolC structural results that reshape PolC inhibitor design priorities.

Antibiotic resistance remains a high-stakes public health threat; structural biology that clarifies drug binding can shorten the path from discovery to viable candidates.

AI reasoning

Antibiotic resistance remains a high-stakes public health threat; structural biology that clarifies drug binding can shorten the path from discovery to viable candidates.

Curated summary

Acurx Pharmaceuticals announced a scientific partnership with Leiden University Medical Center in the Netherlands. The project will study the 3D structure of PolC from MRSA with DNA and an Acurx inhibitor, aiming to accelerate development of antibiotics against resistant Gram-positive pathogens. The work builds on a November 2025 Health-Holland grant and earlier research published in Nature Communications.

Supporting evidence

Source news

Acurx partners with Leiden University Medical Center to map MRSA target and speed antibiotic development

The collaboration aims to determine the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor.

La Grande Observer·1h ago
Read full article at La Grande Observer